Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation

JAMA Oncol. 2021 Feb 1;7(2):177-178. doi: 10.1001/jamaoncol.2020.5742.

Authors

Mark J Ratain^{1

2}, Javid J Moslehi³, Allen S Lichter²

Affiliations

¹ Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
² Value in Cancer Care Consortium, Ann Arbor, Michigan.
³ Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, Tennessee.

PMID: 33237281
DOI: 10.1001/jamaoncol.2020.5742

No abstract available

MeSH terms

Adenine / adverse effects
Adenine / analogs & derivatives
Cardiotoxicity* / etiology
Humans
Piperidines* / adverse effects

Substances

Piperidines
ibrutinib
Adenine